Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson's Disease.

Schneider JS, Aras R, Williams CK, Koprich JB, Brotchie JM, Singh V.

Sci Rep. 2019 Jun 10;9(1):8362. doi: 10.1038/s41598-019-42847-x.

2.

Non-steric-zipper models for pathogenic α-synuclein conformers.

Schuman B, Won A, Brand-Arzamendi K, Koprich JB, Wen XY, Howson PA, Brotchie JM, Yip CM.

APL Bioeng. 2018 May 1;2(2):026105. doi: 10.1063/1.5023460. eCollection 2018 Jun.

3.

Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson's Disease.

Howson PA, Johnston TH, Ravenscroft P, Hill MP, Su J, Brotchie JM, Koprich JB.

J Pharmacol Exp Ther. 2019 Jun;369(3):364-374. doi: 10.1124/jpet.118.255695. Epub 2019 Mar 27.

PMID:
30918068
4.

Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.

Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR.

Mov Disord. 2019 May;34(5):708-716. doi: 10.1002/mds.27565. Epub 2018 Dec 21.

PMID:
30575996
5.

Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?

Fox SH, Brotchie JM.

Eur J Neurosci. 2019 Feb;49(3):399-409. doi: 10.1111/ejn.14173. Epub 2018 Nov 15.

PMID:
30269407
6.

Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia.

Brigham EF, Johnston TH, Brown C, Holt JDS, Fox SH, Hill MP, Howson PA, Brotchie JM, Nguyen JT.

J Pharmacol Exp Ther. 2018 Nov;367(2):373-381. doi: 10.1124/jpet.118.247650. Epub 2018 Aug 7.

PMID:
30087157
7.

Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.

Johnston TH, Lacoste AMB, Visanji NP, Lang AE, Fox SH, Brotchie JM.

Neuropharmacology. 2019 Mar 15;147:11-27. doi: 10.1016/j.neuropharm.2018.05.035. Epub 2018 Jun 1. Review.

PMID:
29907424
8.

A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.

Henrich MT, Geibl FF, Lee B, Chiu WH, Koprich JB, Brotchie JM, Timmermann L, Decher N, Matschke LA, Oertel WH.

Acta Neuropathol Commun. 2018 May 10;6(1):39. doi: 10.1186/s40478-018-0541-1.

9.

Corrigendum to "Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism" [Neurobiol. Dis. 106 (2018) 133-146].

Gleave JA, Arathoon LR, Trinh D, Lizal KE, Giguère N, Barber JEM, Najarali Z, Hassan Khan M, Thiele SL, Semmen MS, Koprich JB, Brotchie JM, Eubanks JH, Trudeau LE, Nash JE.

Neurobiol Dis. 2018 Aug;116:180. doi: 10.1016/j.nbd.2018.02.018. Epub 2018 Mar 20. No abstract available.

PMID:
29571591
10.

DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.

Johnston TH, Versi E, Howson PA, Ravenscroft P, Fox SH, Hill MP, Reidenberg BE, Corey R, Brotchie JM.

Neuropharmacology. 2018 Mar 15;131:116-127. doi: 10.1016/j.neuropharm.2017.11.046. Epub 2017 Nov 29.

PMID:
29197517
11.

Reply to "Can STN DBS protect both nigral somata and innervation of the striatum?"

Koprich JB, Brotchie JM, Musacchio T, Volkmann J, Ip CW.

Ann Neurol. 2017 Nov;82(5):856. doi: 10.1002/ana.25066. Epub 2017 Oct 26. No abstract available.

PMID:
28985651
12.

Animal models of α-synucleinopathy for Parkinson disease drug development.

Koprich JB, Kalia LV, Brotchie JM.

Nat Rev Neurosci. 2017 Sep;18(9):515-529. doi: 10.1038/nrn.2017.75. Epub 2017 Jul 13. Review.

PMID:
28747776
13.

Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism.

Gleave JA, Arathoon LR, Trinh D, Lizal KE, Giguère N, Barber JHM, Najarali Z, Khan MH, Thiele SL, Semmen MS, Koprich JB, Brotchie JM, Eubanks JH, Trudeau LE, Nash JE.

Neurobiol Dis. 2017 Oct;106:133-146. doi: 10.1016/j.nbd.2017.06.009. Epub 2017 Jul 1. Erratum in: Neurobiol Dis. 2018 Mar 20;:.

PMID:
28673739
14.

Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model.

Musacchio T, Rebenstorff M, Fluri F, Brotchie JM, Volkmann J, Koprich JB, Ip CW.

Ann Neurol. 2017 Jun;81(6):825-836. doi: 10.1002/ana.24947. Epub 2017 Jun 9.

15.

AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.

Ip CW, Klaus LC, Karikari AA, Visanji NP, Brotchie JM, Lang AE, Volkmann J, Koprich JB.

Acta Neuropathol Commun. 2017 Feb 1;5(1):11. doi: 10.1186/s40478-017-0416-x.

17.

α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.

Visanji NP, Brotchie JM, Kalia LV, Koprich JB, Tandon A, Watts JC, Lang AE.

Trends Neurosci. 2016 Nov;39(11):750-762. doi: 10.1016/j.tins.2016.09.003. Epub 2016 Oct 21. Review.

PMID:
27776749
18.

Tor1a+/- mice develop dystonia-like movements via a striatal dopaminergic dysregulation triggered by peripheral nerve injury.

Ip CW, Isaias IU, Kusche-Tekin BB, Klein D, Groh J, O'Leary A, Knorr S, Higuchi T, Koprich JB, Brotchie JM, Toyka KV, Reif A, Volkmann J.

Acta Neuropathol Commun. 2016 Oct 3;4(1):108.

19.

Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of Nonhuman Primate Studies and Clinical Trials.

Huot P, Fox SH, Brotchie JM.

J Pharmacol Exp Ther. 2016 Jun;357(3):562-9. doi: 10.1124/jpet.116.232371. Epub 2016 Apr 13. Review.

PMID:
27190169
20.

Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET.

Ma Y, Johnston TH, Peng S, Zuo C, Koprich JB, Fox SH, Guan Y, Eidelberg D, Brotchie JM.

Mov Disord. 2015 Aug;30(9):1283-8. doi: 10.1002/mds.26302.

21.

The link between mitochondrial complex I and brain-derived neurotrophic factor in SH-SY5Y cells--The potential of JNX1001 as a therapeutic agent.

Kim HK, Mendonça KM, Howson PA, Brotchie JM, Andreazza AC.

Eur J Pharmacol. 2015 Oct 5;764:379-84. doi: 10.1016/j.ejphar.2015.07.013. Epub 2015 Jul 8.

PMID:
26164791
22.

The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.

Huot P, Johnston TH, Fox SH, Newman-Tancredi A, Brotchie JM.

Neuropharmacology. 2015 Oct;97:306-11. doi: 10.1016/j.neuropharm.2015.05.033. Epub 2015 Jun 10.

PMID:
26071982
23.

Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.

He Q, Koprich JB, Wang Y, Yu WB, Xiao BG, Brotchie JM, Wang J.

Mol Neurobiol. 2016 May;53(4):2258-68. doi: 10.1007/s12035-015-9173-7. Epub 2015 May 14.

PMID:
25972237
24.

Monoamine reuptake inhibitors in Parkinson's disease.

Huot P, Fox SH, Brotchie JM.

Parkinsons Dis. 2015;2015:609428. doi: 10.1155/2015/609428. Epub 2015 Feb 25. Review.

25.

Gap junction blockers attenuate beta oscillations and improve forelimb function in hemiparkinsonian rats.

Phookan S, Sutton AC, Walling I, Smith A, O'Connor KA, Campbell JC, Calos M, Yu W, Pilitsis JG, Brotchie JM, Shin DS.

Exp Neurol. 2015 Mar;265:160-70. doi: 10.1016/j.expneurol.2015.01.004. Epub 2015 Jan 23.

PMID:
25622779
26.

Management of impulse control disorders in Parkinson's disease: Controversies and future approaches.

Samuel M, Rodriguez-Oroz M, Antonini A, Brotchie JM, Ray Chaudhuri K, Brown RG, Galpern WR, Nirenberg MJ, Okun MS, Lang AE.

Mov Disord. 2015 Feb;30(2):150-9. doi: 10.1002/mds.26099. Epub 2015 Jan 21. Review.

27.

Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study.

Huot P, Johnston TH, Fox SH, Brotchie JM.

Synapse. 2015 Mar;69(3):99-102. doi: 10.1002/syn.21801.

PMID:
25559284
28.

L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.

Huot P, Johnston TH, Koprich JB, Espinosa MC, Reyes MG, Fox SH, Brotchie JM.

Behav Pharmacol. 2015 Feb;26(1-2):101-8. doi: 10.1097/FBP.0000000000000096.

PMID:
25303957
29.

Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models.

Thiele SL, Chen B, Lo C, Gertler TS, Warre R, Surmeier JD, Brotchie JM, Nash JE.

Neurobiol Dis. 2014 Nov;71:334-44. doi: 10.1016/j.nbd.2014.08.006. Epub 2014 Aug 27.

30.

UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.

Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM.

Neuropharmacology. 2014 Jul;82:76-87. doi: 10.1016/j.neuropharm.2014.01.012. Epub 2014 Jan 18.

PMID:
24447715
31.

Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit.

Eskow Jaunarajs KL, Standaert DG, Viegas TX, Bentley MD, Fang Z, Dizman B, Yoon K, Weimer R, Ravenscroft P, Johnston TH, Hill MP, Brotchie JM, Moreadith RW.

Mov Disord. 2013 Oct;28(12):1675-82. doi: 10.1002/mds.25625. Epub 2013 Sep 3.

32.

TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque.

Johnston TH, Huot P, Fox SH, Koprich JB, Szeliga KT, James JW, Graef JD, Letchworth SR, Jordan KG, Hill MP, Brotchie JM.

Neuropharmacology. 2013 Oct;73:337-47. doi: 10.1016/j.neuropharm.2013.06.005. Epub 2013 Jun 14.

PMID:
23770260
33.

Alternating hemiplegia of childhood-related neural and behavioural phenotypes in Na+,K+-ATPase α3 missense mutant mice.

Kirshenbaum GS, Dawson N, Mullins JG, Johnston TH, Drinkhill MJ, Edwards IJ, Fox SH, Pratt JA, Brotchie JM, Roder JC, Clapcote SJ.

PLoS One. 2013;8(3):e60141. doi: 10.1371/journal.pone.0060141. Epub 2013 Mar 20.

34.

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.

Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM.

Pharmacol Rev. 2013 Jan 10;65(1):171-222. doi: 10.1124/pr.111.005678. Print 2013 Jan. Review.

PMID:
23319549
35.

The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques.

Koprich JB, Huot P, Fox SH, Jarvie K, Lang AE, Seeman P, Brotchie JM.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun 3;43:151-6. doi: 10.1016/j.pnpbp.2012.12.008. Epub 2013 Jan 7.

PMID:
23306217
36.

Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.

Huot P, Johnston TH, Snoeren T, Koprich JB, Hill MP, Fox SH, Brotchie JM.

Eur J Neurosci. 2013 Mar;37(5):831-8. doi: 10.1111/ejn.12093. Epub 2013 Jan 3.

PMID:
23281915
37.

Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials.

Kalia LV, Brotchie JM, Fox SH.

Mov Disord. 2013 Feb;28(2):131-44. doi: 10.1002/mds.25273. Epub 2012 Dec 5. Review.

PMID:
23225267
38.

Elevated potassium provides an ionic mechanism for deep brain stimulation in the hemiparkinsonian rat.

Sutton AC, Yu W, Calos ME, Mueller LE, Berk M, Shim J, Molho ES, Brotchie JM, Carlen PL, Shin DS.

Eur J Neurosci. 2013 Jan;37(2):231-41. doi: 10.1111/ejn.12040. Epub 2012 Nov 4.

PMID:
23121286
39.

Selective preservation of MeCP2 in catecholaminergic cells is sufficient to improve the behavioral phenotype of male and female Mecp2-deficient mice.

Lang M, Wither RG, Brotchie JM, Wu C, Zhang L, Eubanks JH.

Hum Mol Genet. 2013 Jan 15;22(2):358-71. doi: 10.1093/hmg/dds433. Epub 2012 Oct 16.

PMID:
23077217
40.

Deep brain stimulation of the substantia nigra pars reticulata improves forelimb akinesia in the hemiparkinsonian rat.

Sutton AC, Yu W, Calos ME, Smith AB, Ramirez-Zamora A, Molho ES, Pilitsis JG, Brotchie JM, Shin DS.

J Neurophysiol. 2013 Jan;109(2):363-74. doi: 10.1152/jn.00311.2012. Epub 2012 Oct 17.

41.

The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset.

Huot P, Johnston TH, Gandy MN, Reyes MG, Fox SH, Piggott MJ, Brotchie JM.

PLoS One. 2012;7(9):e45587. doi: 10.1371/journal.pone.0045587. Epub 2012 Sep 20.

42.

RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study.

Johnston TH, Huot P, Damude S, Fox SH, Jones SW, Rusche JR, Brotchie JM.

Parkinsonism Relat Disord. 2013 Feb;19(2):260-4. doi: 10.1016/j.parkreldis.2012.07.001. Epub 2012 Aug 14.

PMID:
22901956
43.

L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.

Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM.

Neuropharmacology. 2012 Oct;63(5):829-36. doi: 10.1016/j.neuropharm.2012.06.012. Epub 2012 Jun 18.

PMID:
22722022
44.

L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

Huot P, Johnston TH, Koprich JB, Aman A, Fox SH, Brotchie JM.

J Pharmacol Exp Ther. 2012 Aug;342(2):576-85. doi: 10.1124/jpet.112.195693. Epub 2012 May 22.

PMID:
22619253
45.

Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease.

Huot P, Johnston TH, Visanji NP, Darr T, Pires D, Hazrati LN, Brotchie JM, Fox SH.

Mov Disord. 2012 May;27(6):735-42. doi: 10.1002/mds.24964. Epub 2012 Mar 14.

PMID:
22419526
46.

A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates.

Johnston TH, Millar Z, Huot P, Wagg K, Thiele S, Salomonczyk D, Yong-Kee CJ, Gandy MN, McIldowie M, Lewis KD, Gomez-Ramirez J, Lee J, Fox SH, Martin-Iverson M, Nash JE, Piggott MJ, Brotchie JM.

FASEB J. 2012 May;26(5):2154-63. doi: 10.1096/fj.11-195016. Epub 2012 Feb 17.

PMID:
22345403
47.

The serotonergic system in Parkinson's disease.

Huot P, Fox SH, Brotchie JM.

Prog Neurobiol. 2011 Oct;95(2):163-212. doi: 10.1016/j.pneurobio.2011.08.004. Epub 2011 Aug 22. Review.

PMID:
21878363
48.

5-HT(1A) receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanisms.

Huot P, Brotchie JM.

Exp Neurol. 2011 Oct;231(2):195-8. doi: 10.1016/j.expneurol.2011.07.006. Epub 2011 Jul 30. No abstract available.

PMID:
21819982
49.

Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?

Huot P, Fox SH, Newman-Tancredi A, Brotchie JM.

J Pharmacol Exp Ther. 2011 Oct;339(1):2-8. doi: 10.1124/jpet.111.184093. Epub 2011 Jul 22. Review.

PMID:
21784889
50.

Pros and cons of a prion-like pathogenesis in Parkinson's disease.

Hilker R, Brotchie JM, Chapman J.

BMC Neurol. 2011 Jun 20;11:74. doi: 10.1186/1471-2377-11-74.

Supplemental Content

Loading ...
Support Center